Netilmicin, the 1-N-ethyl derivative of sisomicin, is a new semisynthetic aminoglycoside antibiotic which is active against a large number of gram-negative bacteria, including many strains that are resistant to currently available aminoglycosides (9, 10, 14) . As is characteristic for aminoglycosides, netilmicin appears to be excreted into the urine unchanged. Animal studies in rats and dogs with both labeled and nonlabeled netilmicin have failed to indicate that netilmicin is metabolized (J. A. Waitz, personal communication). Studies in experimental animals suggest that netilmicin may be less toxic than gentamicin (8) . Recently, the pharmacokinetics of netilmicin in patients with normal renal function (10) and decreased renal function (17) have been reported. However, information on the elimination of netilmicin in patients with severe renal failure or in those requiring hemodialysis has not been reported. This study was performed to obtain data useful to clinicians caring for such patients. A dosage adjustment table providing therapeutic guidelines was developed.
MATERIALS AND METHODS Subjects. Twenty-five adult subjects were studied. For purposes of analysis, the subjects were divided into four groups on the basis of their renal function: group 1, seven subjects, creatinine clearance (Ccr) 2 70 ml/min; group 2, seven subjects, Ccr 2 25 < 70 ml/min; group 3, six subjects, Ccr 2 4 < 25 ml/min; group 4, five subjects on hemodialysis, who were surgically anephric. The subjects with diminished renal function suffered from a variety of renal diseases including glomerulonephritis, interstitial nephritis, polycystic kidneys, and nephrosclerosis. The subjects on hemodialysis underwent thrice weekly 6-h hemodialyses. They were studied during a 48-h interdialytic period and again during a hemodialysis. A 2-week interval was allowed between the study periods for the hemodialysis patients. Blood specimens for complete blood count, calcium, phosphorus, bilirubin, total protein, albumin, uric acid, blood urea nitrogen, glucose, cholesterol, alkaline phosphatase, lactic acid dehydrogenase, and serum glutamic oxaloacetic acid transaminase were obtained in all subjects. Approval for these studies was (1 -hematocrit). Qb was measured with an electronic flow meter (Ward Associates, San Diego, Calif.). Correction of the clearance measurements for ultrafiltration were not attempted since the total influence of ultrafiltration on clearance is minimal (7) . Statistical analysis was conducted by means of least-squares linear regression. Ninety-five percent confidence limits were generated for the prediction equations defining best fit and are represented by dashed lines in the figures. RESULTS
The distribution of patients according to age and sex is given in Table 1 . The mean netilmicin serum concentrations at each sampling period for the four groups of subjects are shown in Table 2 . Mean peak serum concentrations at the time the infusion was terminated were approximately 11.0,g/ml for group 1 and approximately 9.0 ug/ml for the other three groups. Table 3 summarizes the mean kinetic parameters determined in this study. The Ccr was correlated with the overall elimination rate constant (fi), the serum clearance (CNet), and the volume of distribution (VNet). The regression lines outlined in Fig. 1, 2, and 3 Mean values for the cumulative amount (percentage of dose administered) of netilmicin recovered in the urine are given in Table 5 . One subject in the first group failed to collect a 24-h urine specimen on day 3, accounting for the apparent decrease in the cumulative urinary excretion. The degree of renal impairment was reflected by the percentage of dose recovered in the urine. By day 1, 70% was recovered in the urine for group 1; for group 2, 70% was recovered by day 3 (last day of collection); and for group 3, 36% of the dose administered was recovered in the urine by day 3.
The clearance of netilmicin during hemodialysis, CN.t, with the UF-2 dialyzer was correlated with the plasma flow rate (Qp). The relationship between CN.t and Qp is shown in Fig. 4 . By least-squares regression, the relationship between the two variables is as follows: CNet = 17.10 + 0.12 (Qp), r = 0.65, P < 0.0002. The relationship between the clearance of blood urea nitrogen (CBUN) and blood flow through the (16) , who identified a second half-life for tobramycin and gentamicin that did not correlate with renal function. Their patients were studied after multiple doses, by means of a highly sensitive radioimmunoassay which was capable of detecting very low "washout" serum concentrations (<0.25 ,ig/ml). They were able to explain both the increasing peak and trough concentrations observed during treatment and the detection of the drug in serum and urine long after the last dose, by means of a twocompartment model. The purpose of the present study was to describe the half-life of netilmicin dependent upon renal function so that therapeutic guidelines could be formulated. We found the model independent methods of analysis were best suited for our data.
The results of the present study suggest that the elimination of netilmicin resembles that of other aminoglycoside antibiotics in that it is a function of the glomerular filtration rate (2, 5, 12, 13 (Fig. 1) .
The serum clearance of netilmicin in nornal subjects was 68 ml/min, approximately 60% of the Ccr. This value is similar to clearances reported for amikacin (13) and kanamycin; however, it is greater than that reported for sisomicin (12) . The gentamicin clearance, measured directly in a group of normal subjects, was 61 ml/min, also approximately 60% of the Ccr (11) . Since the non-renal clearance of aminoglycosides is extremely low (Table 4 ) and since protein binding is miniimal or absent (4), it is likely that tubular reabsorption occurs.
The apparent volume of distribution of netilmicin, 20 to 30% of body weight, is similar to those reported for sisomicin (12) , gentamicin, and tobramycin (14) . We observed an inverse relationship between the volume of distribution and the Ccr. (5) , the renal accumulation of the aminoglycoside gentamicin is sharply reduced in patients with chronic renal failure (3). An increase in the tissue distribution of netilmicin in patients with chronic renal failure therefore appears unlikely. Although few of the patients with renal insufficiency who participated in the present study were frankly edematous, attempts were made to expand extracellular fluid volume and hence circulating fluid volume in order to maximize renal function. It is possible that the increased volume of distribution of netilmicin observed in these patients was a result of therapeutic measures used in the course of their renal failure management.
The linear relationship between the elimination constant and the Ccr allowed for the construction of a useful monogram. We have recommended altering the dose rather than the interval of administration; however, the relationship t1/2 = 230/Ccr provides a convenient method of altering the interval instead. Netilmicin is given approximately every third halflife. The new half-life may be estimated from the formula and the new dosage interval calculated accordingly.
In normal subjects, 70% of the administered netilmicin was recovered in the urine during the first 24 h. In a similar study, the recovery of gentamicin after a single intramuscular injection was 74% in 24 h (5) . Seventy percent of the netilmicin was recovered from those with moderate renal impairnent in 3 36% could be recovered during that time from subjects with severe renal failure. The low urine recovery rate is a consequence of the long serum half-life and the limited amount of timed urine data collected.
The clearance of netilmicin during hemodialysis was examined with only one type of dialyzer, the UF-2. Although there was considerable variability, the results were comparable to those reported for gentamicin with the UF-2 dialyzer (6) , suggesting that the characteristics of the two drugs, with respect to dialysis, are similar. The clearance of netilmicin varies directly with the plasma flow rate in a linear fashion over the flow range clinically used. The amount of netilmicin removed by dialysis is not only a function of the plasma flow rate, but also of the length of the procedure. Therapeutic adjustments will be required with respect to both of these parameters. Assuming a volume of distribution approximating 340 ml/kg, a 70-kg patient undergoing a 5-h dialysis at a plasma flow rate of 200 ml/min would have a netilmicin clearance approaching 12 liters for that time interval. Therefore, with a standardized dialysis, 50% of the netilmicin may be lost. If the dialysis patient is initially given a 2-mg/kg loading dose of netilmicin, and subsequently receives the drug in "anephric" doses during the interdialytic period, at least one-half of the initial loading dose of 1 mg/kg would be required after dialysis. In such circumstances, as with any drug with a fairly narrow therapeutic margin of safety, serum concentrations should be monitored.
